• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黏多糖贮积症 I 型小鼠关节疾病的特征。

Characterization of joint disease in mucopolysaccharidosis type I mice.

机构信息

Programa de pós-graduação em medicina: ciências medicas, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Brazil.

出版信息

Int J Exp Pathol. 2013 Oct;94(5):305-11. doi: 10.1111/iep.12033. Epub 2013 Jun 21.

DOI:10.1111/iep.12033
PMID:23786352
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3781776/
Abstract

Mucopolysaccharidoses (MPS) are lysosomal storage disorders characterized by mutations in enzymes that degrade glycosaminoglycans (GAGs). Joint disease is present in most forms of MPS, including MPS I. This work aimed to describe the joint disease progression in the murine model of MPS I. Normal (wild-type) and MPS I mice were sacrificed at different time points (from 2 to 12 months). The knee joints were collected, and haematoxylin-eosin staining was used to evaluate the articular architecture. Safranin-O and Sirius Red staining was used to analyse the proteoglycan and collagen content. Additionally, we analysed the expression of the matrix-degrading metalloproteinases (MMPs), MMP-2 and MMP-9, using immunohistochemistry. We observed progressive joint alterations from 6 months, including the presence of synovial inflammatory infiltrate, the destruction and thickening of the cartilage extracellular matrix, as well as proteoglycan and collagen depletion. Furthermore, we observed an increase in the expression of MMP-2 and MMP-9, which could conceivably explain the degenerative changes. Our results suggest that the joint disease in MPS I mice may be caused by a degenerative process due to increase in proteases expression, leading to loss of collagen and proteoglycans. These results may guide the development of ancillary therapies for joint disease in MPS I.

摘要

黏多糖贮积症(MPS)是一种溶酶体贮积病,其特征是降解糖胺聚糖(GAG)的酶发生突变。大多数 MPS 形式都存在关节疾病,包括 MPS I。本研究旨在描述 MPS I 小鼠模型中的关节疾病进展。正常(野生型)和 MPS I 小鼠在不同时间点(从 2 个月到 12 个月)被处死。收集膝关节,进行苏木精-伊红染色以评估关节结构。番红 O 和天狼星红染色用于分析蛋白聚糖和胶原含量。此外,我们使用免疫组织化学分析基质降解金属蛋白酶(MMPs),MMP-2 和 MMP-9 的表达。我们观察到从 6 个月开始关节逐渐发生改变,包括滑膜炎症浸润、软骨细胞外基质的破坏和增厚,以及蛋白聚糖和胶原的耗竭。此外,我们观察到 MMP-2 和 MMP-9 的表达增加,这可能可以解释退行性变化。我们的结果表明,MPS I 小鼠的关节疾病可能是由于蛋白酶表达增加导致的退行性过程引起的,从而导致胶原和蛋白聚糖的丧失。这些结果可能为 MPS I 中的关节疾病的辅助治疗提供指导。

相似文献

1
Characterization of joint disease in mucopolysaccharidosis type I mice.黏多糖贮积症 I 型小鼠关节疾病的特征。
Int J Exp Pathol. 2013 Oct;94(5):305-11. doi: 10.1111/iep.12033. Epub 2013 Jun 21.
2
Evidence that glycosaminoglycan storage and collagen deposition in the cauda epididymidis does not impair sperm viability in the Mucopolysaccharidosis type I mouse model.证据表明,黏多糖贮积症 I 型小鼠模型的尾部附睾中糖胺聚糖的储存和胶原沉积并不损害精子活力。
Reprod Fertil Dev. 2020 Feb;32(3):304-312. doi: 10.1071/RD19144.
3
Biomechanical and histological characterization of MPS I mice femurs.MPS I 型小鼠股骨的生物力学和组织学特性研究。
Acta Histochem. 2021 Feb;123(2):151678. doi: 10.1016/j.acthis.2020.151678. Epub 2021 Jan 9.
4
Extracellular matrix disruption is an early event in the pathogenesis of skeletal disease in mucopolysaccharidosis I.细胞外基质破坏是黏多糖贮积症I型骨骼疾病发病机制中的早期事件。
Mol Genet Metab. 2015 Feb;114(2):146-55. doi: 10.1016/j.ymgme.2014.09.012. Epub 2014 Oct 7.
5
Progressive heart disease in mucopolysaccharidosis type I mice may be mediated by increased cathepsin B activity.I型黏多糖贮积症小鼠的进行性心脏病可能由组织蛋白酶B活性增加介导。
Cardiovasc Pathol. 2017 Mar-Apr;27:45-50. doi: 10.1016/j.carpath.2017.01.001. Epub 2017 Jan 6.
6
Adenoviral gene transfer of interleukin-1 in combination with oncostatin M induces significant joint damage in a murine model.在小鼠模型中,白细胞介素-1与制瘤素M的腺病毒基因转移联合诱导显著的关节损伤。
Am J Pathol. 2003 Jun;162(6):1975-84. doi: 10.1016/S0002-9440(10)64330-1.
7
Morphologic description of male reproductive accessory glands in a mouse model of mucopolysaccharidosis type I (MPS I).黏多糖贮积症 I 型(MPS I)小鼠模型中雄性附属性腺的形态学描述。
J Mol Histol. 2020 Apr;51(2):137-145. doi: 10.1007/s10735-020-09864-x. Epub 2020 Mar 11.
8
Sexual behaviour in a murine model of mucopolysaccharidosis type I (MPS I).黏多糖贮积症Ⅰ型(MPS I)小鼠模型中的性行为。
PLoS One. 2019 Dec 13;14(12):e0220429. doi: 10.1371/journal.pone.0220429. eCollection 2019.
9
Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.关节内注射 rhIDUA 进行酶替代治疗在黏多糖贮积症 I 型犬模型中安全、耐受良好,并减少了关节 GAG 的储存。
Mol Genet Metab. 2014 Aug;112(4):286-93. doi: 10.1016/j.ymgme.2014.05.015. Epub 2014 Jun 6.
10
Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice.黏多糖贮积症Ⅰ型小鼠进行性运动功能障碍的证据。
Behav Brain Res. 2012 Jul 15;233(1):169-75. doi: 10.1016/j.bbr.2012.04.051. Epub 2012 May 9.

引用本文的文献

1
Mesenchymal Stem Cell-Derived Extracellular Vesicles: Seeking into Cell-Free Therapies for Bone-Affected Lysosomal Storage Disorders.间充质干细胞衍生的细胞外囊泡:探寻针对骨受累溶酶体贮积症的无细胞疗法
Int J Mol Sci. 2025 Jul 4;26(13):6448. doi: 10.3390/ijms26136448.
2
Development of a novel tool for individual treatment trials in mucopolysaccharidosis.一种用于黏多糖贮积症个体治疗试验的新型工具的研发。
J Inherit Metab Dis. 2025 Jan;48(1):e12816. doi: 10.1002/jimd.12816. Epub 2024 Nov 21.
3
Evaluation of tendon and ligament microstructure and mechanical properties in a canine model of mucopolysaccharidosis I.评估黏多糖贮积症 I 犬模型中的肌腱和韧带微观结构及力学性能。
J Orthop Res. 2024 Jul;42(7):1409-1419. doi: 10.1002/jor.25813. Epub 2024 Feb 18.
4
An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis.一种用于黏多糖贮积症循证、个性化治疗试验的创新工具。
Pharmaceutics. 2023 May 22;15(5):1565. doi: 10.3390/pharmaceutics15051565.
5
Proteomics identifies novel biomarkers of synovial joint disease in a canine model of mucopolysaccharidosis I.蛋白质组学鉴定黏多糖贮积症 I 犬模型中滑膜关节疾病的新型生物标志物。
Mol Genet Metab. 2023 Feb;138(2):107371. doi: 10.1016/j.ymgme.2023.107371. Epub 2023 Jan 4.
6
Effects of lithium administration on vertebral bone disease in mucopolysaccharidosis I dogs.锂剂治疗对黏多糖贮积症 I 型犬的椎骨疾病的影响。
Bone. 2022 Jan;154:116237. doi: 10.1016/j.bone.2021.116237. Epub 2021 Oct 22.
7
Biomarkers for prediction of skeletal disease progression in mucopolysaccharidosis type I.用于预测I型黏多糖贮积症骨骼疾病进展的生物标志物。
JIMD Rep. 2020 Dec 8;58(1):89-99. doi: 10.1002/jmd2.12190. eCollection 2021 Mar.
8
Growth Plate Pathology in the Mucopolysaccharidosis Type VI Rat Model-An Experimental and Computational Approach.VI型黏多糖贮积症大鼠模型中的生长板病理学——一种实验与计算方法
Diagnostics (Basel). 2020 May 31;10(6):360. doi: 10.3390/diagnostics10060360.
9
Cathepsins in the Pathophysiology of Mucopolysaccharidoses: New Perspectives for Therapy.黏多糖贮积症发病机制中的组织蛋白酶:治疗的新视角。
Cells. 2020 Apr 15;9(4):979. doi: 10.3390/cells9040979.
10
Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice.CRISPR/Cas9 系统对新生鼠的非病毒基因编辑可改善黏多糖贮积症 I 表型的一些心血管、呼吸和骨骼疾病特征。
Gene Ther. 2020 Feb;27(1-2):74-84. doi: 10.1038/s41434-019-0113-4. Epub 2019 Dec 11.

本文引用的文献

1
Evidence of a progressive motor dysfunction in Mucopolysaccharidosis type I mice.黏多糖贮积症Ⅰ型小鼠进行性运动功能障碍的证据。
Behav Brain Res. 2012 Jul 15;233(1):169-75. doi: 10.1016/j.bbr.2012.04.051. Epub 2012 May 9.
2
Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation.黏多糖贮积症 VII 型小鼠主动脉扩张的发病机制可能涉及补体激活。
Mol Genet Metab. 2011 Dec;104(4):608-19. doi: 10.1016/j.ymgme.2011.08.018. Epub 2011 Aug 24.
3
Basic methods in histopathology of joint tissues.关节组织病理组织学的基本方法。
Osteoarthritis Cartilage. 2010 Oct;18 Suppl 3:S113-6. doi: 10.1016/j.joca.2010.05.026.
4
Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model.基因治疗增强了造血细胞移植的疗效,并在小鼠模型中完全纠正了黏多糖贮积症 I 型表型。
Blood. 2010 Dec 9;116(24):5130-9. doi: 10.1182/blood-2010-04-278234. Epub 2010 Sep 16.
5
[Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].[黏多糖贮积症 I、II 和 VI 的酶替代疗法:一组巴西专家的建议]
Rev Assoc Med Bras (1992). 2010 May-Jun;56(3):271-7. doi: 10.1590/s0104-42302010000300009.
6
Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients.重组人α-L-艾杜糖苷酸酶(拉罗尼酶)治疗黏多糖贮积症 I 型患者上肢活动受限的疗效。
J Inherit Metab Dis. 2010 Apr;33(2):151-7. doi: 10.1007/s10545-010-9059-9. Epub 2010 Mar 9.
7
Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities.黏多糖贮积症 I 中糖胺聚糖介导的组织蛋白酶 K 胶原降解活性丧失导致破骨细胞和生长板异常。
Am J Pathol. 2009 Nov;175(5):2053-62. doi: 10.2353/ajpath.2009.090211. Epub 2009 Oct 15.
8
Mechanism of shortened bones in mucopolysaccharidosis VII.黏多糖贮积症VII型中骨骼缩短的机制。
Mol Genet Metab. 2009 Jul;97(3):202-11. doi: 10.1016/j.ymgme.2009.03.005. Epub 2009 Mar 25.
9
Characterization of metalloprotease cleavage products of human articular cartilage.人关节软骨金属蛋白酶裂解产物的特性分析
Arthritis Rheum. 2008 Aug;58(8):2420-31. doi: 10.1002/art.23654.
10
Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice.弹性蛋白酶蛋白的上调导致黏多糖贮积症I型小鼠的主动脉扩张。
Mol Genet Metab. 2008 Jul;94(3):298-304. doi: 10.1016/j.ymgme.2008.03.018. Epub 2008 May 13.